• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Annual Report 30th April 2025

by alex | Apr 30, 2025 | Financial Info

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Investor Update: 24 April 2025

by chantal | Apr 25, 2025 | Investor Presentations

Scancell’s new partnership with the NHS Vaccine Launch Pad (CLVP) March 2025

by admin | Apr 14, 2025 | Investor Presentations

Scancell FY25 Interim Results Presentation

by admin | Feb 11, 2025 | Investor Presentations

CEO Phil L’Huillier gives update on Scancell progress to Proactive

by admin | Feb 11, 2025 | Investor Presentations

FY25 Interim Results: Products, People and Progress

by chantal | Jan 30, 2025 | Investor Presentations

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy